Form 4: Amgen Director Michael V. Drake Reports Acquisition of Common Stock

Director Michael V. Drake reports acquiring Amgen common stock through vested Restricted Stock Units (RSUs) and dividend equivalents.

Summary

• On November 4, 2024, Michael V. Drake, a director of Amgen Inc., acquired 220.8829 shares of Amgen common stock.
• The acquisition was a result of vested Restricted Stock Units (RSUs) granted under the Amgen Inc. 2009 Director Incentive Program.
• The RSUs vested immediately and are payable in shares of Amgen's common stock on a one-to-one basis.
• The reported transaction also includes 140 Dividend Equivalents (DEs) granted pursuant to the Director Program.
• Following the transaction, Drake beneficially owns 3,552.1796 shares of Amgen common stock.

Sentiment

Score: 6

Explanation: Neutral sentiment as the filing simply reports a standard transaction related to director compensation.

Positives

• The acquisition of shares by a director can be seen as a positive signal, indicating confidence in the company's future prospects.

Future Outlook

The vested RSUs may be deferred by the director, in which case payment will occur according to the elected deferral schedule.

Industry Context

Director share acquisitions are common and closely monitored as they can reflect management's sentiment about the company's performance and future.

Comparison to Industry Standards

• Director ownership is a common metric used to assess alignment of interests between management and shareholders.
• Comparing Drake's holdings to those of directors at peer companies like Johnson & Johnson or Pfizer could provide context on the significance of his stake.

Stakeholder Impact

• The transaction has a minor positive impact on shareholders as it signals director confidence.

Key Dates